Novo Nordisk A/S
NVO
$125.79
-$0.37-0.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 33.71B | 30.81B | 28.40B | 26.37B | 25.03B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.71B | 30.81B | 28.40B | 26.37B | 25.03B |
| Cost of Revenue | 5.19B | 4.88B | 4.44B | 4.16B | 4.02B |
| Gross Profit | 28.52B | 25.93B | 23.96B | 22.22B | 21.00B |
| SG&A Expenses | 8.94B | 8.32B | 7.98B | 7.42B | 7.16B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -17.31M | -76.35M | -70.17M | -93.69M | -148.08M |
| Total Operating Expenses | 18.62B | 17.33B | 16.12B | 14.95B | 14.32B |
| Operating Income | 15.09B | 13.48B | 12.28B | 11.42B | 10.71B |
| Income Before Tax | 15.19B | 13.45B | 11.79B | 10.65B | 9.79B |
| Income Tax Expenses | 3.05B | 2.60B | 2.28B | 2.07B | 1.92B |
| Earnings from Continuing Operations | 12.15K | 10.84K | 9.51K | 8.58K | 7.87K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.15B | 10.84B | 9.51B | 8.58B | 7.87B |
| EBIT | 15.09B | 13.48B | 12.28B | 11.42B | 10.71B |
| EBITDA | 16.24B | 14.59B | 13.30B | 12.36B | 11.65B |
| EPS Basic | 2.71 | 2.41 | 2.11 | 1.90 | 1.74 |
| Normalized Basic EPS | 2.15 | 1.90 | 1.66 | 1.50 | 1.38 |
| EPS Diluted | 2.70 | 2.41 | 2.11 | 1.89 | 1.73 |
| Normalized Diluted EPS | 2.14 | 1.89 | 1.66 | 1.50 | 1.37 |
| Average Basic Shares Outstanding | 17.93B | 17.97B | 18.02B | 18.07B | 18.12B |
| Average Diluted Shares Outstanding | 17.98B | 18.03B | 18.08B | 18.13B | 18.18B |
| Dividend Per Share | 1.36 | 1.00 | 1.00 | 0.86 | 0.86 |
| Payout Ratio | 37.90% | 42.45% | 41.47% | 45.97% | 46.63% |
